5 employees
CyGenica uses a non-viral, non-toxic platform to develop in vitro and in vivo delivery solutions for drugs and antibiotics.
2017
$1.4M
from 1 investors over 1 rounds
CyGenica raised $1.4M on June 8, 2021
Investors: SOSV - The Accelerator VC